Insmed is a biopharmaceutical company focused on improving the lives of patients with rare diseases. The company's proprietary Pulmovance? technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. The company's product pipeline: INS1007, an oral, reversible inhibitor of dipeptidyl peptidase 1, an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow; INS1009, an investigational inhaled treprostinil prodrug formulation that has the potential to manage certain of the limitations of existing prostanoid therapies.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.